NASPCC Symposium on Immuno-Oncology in Prostate Cancer: Current and Future Trends
June 24, 2021
10:00 am – 2:30 pm (Pacific)
Pillars of Cancer Therapy

Surgery

Radiotherapy

Chemotherapy

Immune therapy

Antibody Immunotherapy

- Antibody Dependent Cellular Cytotoxicity (ADCC)
  *Rituximab (NHL)
  (Beck et al., 1999)

Antibody Immunotherapy
• Antibody Dependent Cellular Cytotoxicity (ADCC)
  *Rituximab (NHL)
  (Beck et al., 1999)

Cancer Vaccines
• Elicit anti-tumor T-cell responses by inducing tumor antigen expression on DCs
  *Provenge
  (Hahn et al., 2012)
Antibody Immunotherapy
• Antibody Dependent Cellular Cytotoxicity (ADCC)
  *Rituximab (NHL)
  (Beck et al., 1999)

Cancer Vaccines
• Elicit anti-tumor T-cell responses by inducing tumor antigen expression on DCs
  *Provenge
  (Hahn et al., 2012)

Bi-Specific T cell engagers
• Anti-CD3/CD19 Bi-specific Blinatumomab (ALL)
  (Robinson HR. et al., 2018)
Cancer Immunotherapy

Antibody Immunotherapy
- Antibody Dependent Cellular Cytotoxicity (ADCC)
  *Rituximab (NHL)
  (Beck et al, 1999)

Cancer Vaccines
- Elicit anti-tumor T-cell responses by inducing tumor antigen expression on DCs
  *Provenge
  (Hahn et al, 2012)

Bi-Specific T cell engagers
- Anti-CD3/CD19 Bi-specific Blinatumomab (ALL)
  (Robinson HR. et al., 2018)

Checkpoint Blockade
- Anti-PD1 / Anti-CTLA-4 mAbs
  *Nivolumab/Ipilimumab
  Metastatic melanoma
  (Ascierto et al., 2012)

Escape mechanisms in the majority of cancers
- MHC down-regulation / defective antigen presentation of TAAs
- Immunosuppressive tumor-infiltrating immune cells

Adapted from Roberts et al, Leuk & Lymphoma 2017
Today’s Landscape of Immunotherapy

- **T cell-targeted immunomodulators**
  - 2020: 533
  - 2019: 408
  - 2018: 419
  - 2017: 223

- **Other immunomodulators**
  - 2020: 639
  - 2019: 615
  - 2018: 581
  - 2017: 262

- **Cell therapies**
  - 2020: 257
  - 2019: 616
  - 2018: 448
  - 2017: 179

- **Cancer vaccines**
  - 2020: 874
  - 2019: 445
  - 2018: 397

Clinical stage:
- Approved
- Phase III
- Phase II
- Phase I
- Preclinical
Today’s Landscape of Immunotherapy

Upadhaya et al. Nat Rev Drug Disc 2020
<table>
<thead>
<tr>
<th>Time</th>
<th>Session One</th>
<th>Session Two</th>
</tr>
</thead>
</table>
| 10:15 am – 10:35 am | **Redirecting T-Cells for Prostate Cancer Immunotherapy**  
  *Lawrence Fong MD*  
  University of California, San Francisco | 12:30 pm – 12:50 pm  
  **Upcoming Clinical Trial of DLL3/CF3 BiTE in Neuroendocrine Prostate Cancer**  
  *Rahul Aggarwal, MD*  
  University of California, San Francisco |
| 10:40 am – 11:00 am | **CAR-T Development in Sub-Types of Prostate Cancer: How Mechanistic Biology Impacts Future Therapies**  
  *John Lee, MD, PhD*  
  Fred Hutchinson Cancer Center | 12:55 pm – 1:15 pm  
  **Anti-CTLA-4-Therapy in Prostate Cancer**  
  *Sumit Subudhi, MD, PhD*  
  UT MD Anderson Cancer Center |
| 11:05 am – 11:25 am | **Chimeric Antigen Receptor T-Cell Therapies for Advanced Prostate Cancer: Clinical Trials (and Tribulations)**  
  *Vivek Narayen, MD, MS*  
  University of Pennsylvania | 1:20 pm – 1:40 pm  
  **The Quest for an Effective Immunotherapy for Prostate Cancer**  
  *James Gulley, MD, PhD*  
  National Institutes of Health (NIH) |
| 11:30 am – 11:50 am | **Advancing CAR-T Cells for Prostate Cancer**  
  *Saul Priceman, PhD*  
  City of Hope Medical Center | 1:45 pm – 2:05 pm  
  **Allogenic Approaches to Cell Therapy for Tumors of Various Sorts**  
  *Charles Drake, MD, PhD*  
  New York-Presbyterian/Columbia |
| 11:50 am – 12:10 pm | **Panel Discussion**                                                      | 2:10 pm – 2:30 pm  
  **Panel Discussion**                                                      |
| 12:10 pm – 12:25 pm | **Break**                                                       | 2:30 pm  
  **Closing Remarks**                                                       |